Erasca (ERAS) Jefferies 2024 Global Healthcare Conference summary

Strategic updates and business development

• Announced successful in-licensing of a RAS-targeting franchise, including ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor), both with best-in-class or first-in-class potential in RAS-mutant solid tumors.

• Completed an oversubscribed $184 million financing, extending cash runway into the first half of 2027.

• Focused exclusively on the RAS-MAP kinase pathway, targeting upstream/downstream nodes, RAS directly, and key escape routes.

• Assembled a deep, modality-agnostic, pathway-focused pipeline, including naporafenib, ERAS-0015, ERAS-4001, and a bispecific EGFR antibody.

• Building late-stage development capabilities as the company transitions into a phase III organization.

Clinical pipeline and trial progress

• Naporafenib is in phase 1b (SEACRAFT-1) for pan-RAS Q61X solid tumors, with phase III (SEACRAFT-2) for NRAS mutant melanoma starting this quarter.

• SEACRAFT-1 targets high unmet need tumors; phase 1b data expected in Q4 2024.

• SEACRAFT-2 is a randomized, two-stage phase III trial with dual primary endpoints of PFS and OS; stage 1 data expected in 2025.

• Both trials implement primary prophylaxis for rash to improve safety and tolerability.

• FDA FastTrack designation granted for naporafenib plus trametinib in NRAS mutant melanoma.

Preclinical and mechanistic insights

• ERAS-0015 and ERAS-4001 show high potency, strong oral bioavailability, and robust IP protection to 2043.

• ERAS-0015 demonstrates 10-fold higher potency and longer tumor tissue residence time compared to reference compounds in multiple in vivo models.

• ERAS-4001 is potent against pan-KRAS mutations, spares HRAS and NRAS wild type, and shows promising efficacy and tolerability in animal models.

• Both molecules exhibit favorable ADME properties and high oral bioavailability across species.

• Combination strategies, such as pairing ERAS-4001 with ERAS-0015, are being explored for enhanced RAS pathway inhibition.